amylin


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to amylin: Symlin

dextrin, amylin, starch gum

A starch-like compound having strong adhesive properties; an amorphous, odorless, sweetish-tasting, white, water-soluble gum; used as a wallpaper adhesive.
References in periodicals archive ?
Bristol-Myers Squibb agreed at the end of June to take over Amylin for USD5.
which like Amylin has headquarters in San Diego, says its new drug application (NDA) for lorcaserin --an internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss--has been accepted for filing by the Food and Drug Administration.
The expansion of the collaboration covers the co-development and marketing of products in the Amylin Pharmaceuticals portfolio, which include BYETTA([R]) (exenatide) and BYDUREON([R]) (exenatide extended-release for injectable suspension/exenatide 2 mg powder and solvent for prolonged release suspension for injection) for the treatment of type 2 diabetes, metreleptin, an investigational leptin analogue currently under review by the U.
The board of directors of Amylin has unanimously recommended that Amylin's stockholders tender their shares into the tender offer.
This payment will be made following the completion of Bristol-Myers Squibba[euro](tm)s acquisition of Amylin.
are serving as financial advisors to Amylin in connection with the transactions and Amylin is represented by Skadden, Arps, Slate, Meagher & Flom LLP.
Amylin and the banks declined to comment on the information when reached by Bloomberg, while Sanofi was not immediately available, Bloomberg said.
Lilly chairman and chief executive officer Sidney Taurel says the approval marks a milestone for the collaboration between his company and Amylin.
Bristol-Myers Squibb initiated on July 10, 2012, through its wholly-owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin for $31.
Since then, the buyer has not contacted Amylin, the informed sources told the news agency.
8 November 2011 - Amylin Pharmaceuticals Inc (NASDAQ:AMLN) and Eli Lilly and Co (NYSE:LLY) said today they have agreed to end their partnership for exenatide and resolve the outstanding litigation between the companies.
Lilly and Amylin indicate marketing approval from the Food and Drug Administration could be sought as early as 2004.